



Office de la Propriété

Intellectuelle  
du Canada

Un organisme  
d'Industrie Canada

Canadian  
Intellectual Property  
Office

An agency of  
Industry Canada

CA 2428994 C 2010/05/11

(11)(21) **2 428 994**

(12) **BREVET CANADIEN**  
**CANADIAN PATENT**

(13) **C**


(86) Date de dépôt PCT/PCT Filing Date: 2001/11/08  
(87) Date publication PCT/PCT Publication Date: 2002/08/15  
(45) Date de délivrance/Issue Date: 2010/05/11  
(85) Entrée phase nationale/National Entry: 2003/05/08  
(86) N° demande PCT/PCT Application No.: US 2001/046841  
(87) N° publication PCT/PCT Publication No.: 2002/062260  
(30) Priorités/Priorities: 2000/11/08 (US60/246,709);  
2000/11/08 (US60/246,708); 2000/11/08 (US60/246,707);  
2000/11/08 (US60/246,689)

(51) Cl.Int./Int.Cl. *A61L 12/12*(2006.01),  
*A61L 12/08*(2006.01)  
(72) Inventeur/Inventor:  
SMITH, FRANCIS XAVIER, US  
(73) Propriétaire/Owner:  
FXS VENTURES, LLC, US  
(74) Agent: GOWLING LAFLEUR HENDERSON LLP

(54) Titre : SOLUTIONS AMELIOREES OPHTALMIQUES ET POUR LENTILLES DE CONTACT CONTENANT DES FORMES DE VITAMINE B  
(54) Title: IMPROVED OPHTHALMIC AND CONTACT LENS SOLUTIONS CONTAINING FORMS OF VITAMIN B

(57) Abrégé/Abstract:

The present invention relates to improved ophthalmic solutions that employ select B vitamins; pyridoxine and its salts; and thiamine and its salts in order to more effectively preserve solutions and to reduce the degree to which cationic preservatives will deposit on contact lenses. Ophthalmic solutions are here understood to include contact lens treatment solutions, such as cleaners, soaking solutions, conditioning solutions and lens storage solutions, as well as wetting solutions and in-eye solutions for treatment of eye conditions.



## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
15 August 2002 (15.08.2002)

PCT

(10) International Publication Number  
WO 02/062260 A3(51) International Patent Classification<sup>7</sup>: A61K 31/74

(21) International Application Number: PCT/US01/46841

(22) International Filing Date:  
8 November 2001 (08.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/246,689	8 November 2000 (08.11.2000)	US
60/246,707	8 November 2000 (08.11.2000)	US
60/246,708	8 November 2000 (08.11.2000)	US
60/246,709	8 November 2000 (08.11.2000)	US

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:  
17 October 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (for all designated States except US):  
**BIO-CONCEPT LABORATORIES** [US/US]; Suite 101, 4 Tinkham Avenue, Derry, NH 03038 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **SMITH, Francis, Xavier** [US/US]; 22 Fox Run Lane, Salem, NH 03079 (US).(74) Agent: **BLANK, Christopher, E.**; Jaeckle Fleischmann & Mugel, LLP, 39 State Street, Rochester, NY 14614-1310 (US).

WO 02/062260 A3

(54) Title: IMPROVED OPHTHALMIC AND CONTACT LENS SOLUTIONS CONTAINING FORMS OF VITAMIN B

(57) Abstract: The present invention relates to improved ophthalmic solutions that employ select B vitamins; pyridoxine and its salts; and thiamine and its salts in order to more effectively preserve solutions and to reduce the degree to which cationic preservatives will deposit on contact lenses. Ophthalmic solutions are here understood to include contact lens treatment solutions, such as cleaners, soaking solutions, conditioning solutions and lens storage solutions, as well as wetting solutions and in-eye solutions for treatment of eye conditions.

## Improved Ophthalmic and Contact Lens Solutions Containing forms of Vitamin B

### Field of the Invention

The present invention relates to the field of ophthalmic solutions and their  
5 uses. In particular the invention relates to contact lens cleaning solutions, contact lens  
rinsing and storing solutions, solution to deliver active pharmaceutical agents to the  
eye, solutions for disinfecting ophthalmic devices and the like.

### Background

The present invention relates to the field of ophthalmic solutions and  
10 especially to the aspects of preservative efficacy and comfort after prolonged use.  
These ophthalmic solutions have been used for some period of time and are available  
as over the counter products. Solutions that are used in direct contact with corneal  
tissue such as the delivery of active pharmaceutical agent to the eye, or indirectly,  
such as the cleaning, conditioning or storage of devices that will come in contact with  
15 corneal tissue, such as contact lenses, there is a need to insure that these solutions do  
not introduce sources of bacterial or other microbial infection. Thus preservatives are  
included to reduce the viability of microbes in the solution and to lessen the chance of  
contamination of the solution by the user since many of the solutions are bought,  
opened, sealed and then reused.

20 State of the art preservative agents include polyhexamethylene  
biguanide (phmb), polyquad™, chlorhexidine, and benzalkonium chloride, and the  
like, all of which at some concentration irritate corneal tissue and lead to user  
discomfort. Therefore, a solution that employs a given amount of a preservative  
agent, but which is made more effective by addition of an agent that is not a  
25 preservative agent would be desired.

### Summary of the Invention

The present invention relates to improved ophthalmic solutions that  
employ select B vitamins; pyridoxine and its salts; and thiamine and its salts in order  
to more effectively preserve solutions and to reduce the degree to which cationic

preservatives will deposit on contact lenses. Ophthalmic solutions are here understood to include contact lens treatment solutions, such as cleaners, soaking solutions, conditioning solutions and lens storage solutions, as well as wetting solutions and in-eye solutions for treatment of eye conditions.

## 5    **Detailed Description**

The solutions specifically described herein have 0.001 to about 1 percent of select B vitamins; pyridoxine and its salts; and thiamine and its salts in combination with other active ingredients useful in ophthalmic solutions such as tonicity agent, buffers, preservatives, surfactants, and antimicrobial agents.

10            The B family of vitamins includes thiamine (B1), riboflavin (B2), niacin (B3), pantothenic acid (B5), pyridoxine (B6), and cobalamin (B12). While each form of B vitamin is chemically distinct, they are often found in the same nutritional sources and hence deficiency in one is often related to deficiency in the other forms. Metabolically, they work with one another to bolster metabolism, 15 enhance immune and nervous system function, maintain healthy skin and muscle tone, and promote cell growth and division. They may also relieve stress, depression, and cardiovascular disease. A deficiency in one B vitamin often means that intake of all B vitamins is low which is why B as a nutritional source are often provided in multivitamin or B-complex formulae.

20            Niacin contributes to a great number of bodily processes. Among other things niacin helps convert food into energy, build red blood cells, synthesize hormones, fatty-acids and steroids. The body uses niacin in the process of releasing energy from carbohydrates. Niacin is also needed to form fat from carbohydrates and to process alcohol. Niacin also helps regulate cholesterol.

25            Pyridoxine is needed to make serotonin, melatonin, and dopamine. Vitamin B-6 is an essential nutrient in the regulation of mental processes and possibly assists in mood and many other health concerns.

30            Cobalamin is needed for normal nerve cell activity. Vitamin B-12 is also needed for DNA replication, and production of the mood-affecting substance called SAMe (S-adenosyl-L-methionine). Vitamin B-12 works with folic acid to control

homocysteine levels. An excess of homocysteine, which is an amino acid (protein building block), may increase the risk of heart disease, stroke, and perhaps osteoporosis and Alzheimer's disease.

Other compounds such as folic acid or folate are active in combination 5 with the B vitamins and are needed to synthesize DNA. DNA allows cells to replicate normally. Folic acid is especially important for the cells of a fetus when a woman is pregnant. Folic acid is also needed to make SAMe and keep homocysteine levels in the blood from rising. Folic acid (pteroylglutamic acid) is not active as such in the mammalian organism, but rather is enzymatically reduced to tetrahydrofolic 10 acid (THFA), the coenzyme form. An interrelationship exists with vitamin B12 and folate metabolism that further involves vitamin B6: folate coenzymes participate in a large number of metabolic reactions in which there is a transfer of a one-carbon unit.

Pantothenic acid, also sometimes referred to as coenzyme A, is the 15 physiologically active form of pantothenic acid, and serves a vital role in metabolism as a coenzyme for a variety of enzyme-catalyzed reactions involving transfer of acetyl (two-carbon) groups. Surprisingly, pantothenic acid is essential for the growth of various microorganisms, including many strains of pathogenic bacteria. Pantothenic Acid is a metabolite of dexpanthenol and panthenol.

In the form of contact lens rinsing solutions and/or pharmaceutical agent 20 delivery system the solutions will contain, in addition to the lens or the pharmaceutical agent 0.0001 to about 1.0 weight percent of one of the vitamin B forms or a vitamin B co-metabolite chosen from the group consisting of thiamine (B1), riboflavin (B2), niacin (B3), pantothenic acid (B5), pyridoxine (B6), and cobalamin (B12), folic acid, carnitine, dexpanthenol and panthenol.

25 The preservatives that are specifically useful are cationic preservative such as polyhexamethylene biguanide (phmb), polyquad™, chlorhexidine, and benzalkonium chloride, as well as other cationic preservatives that may prove useful in the present invention as well. The cationic preservatives are used at effective amounts as preservatives, and in the instance of PHMB from 0.0001 percent by 30 weight to higher levels of about 0.01 weight percent.

It was found that an unexpected preservative efficacy was displayed when inositol was used in conjunction with the cationic preservative. The other components of the solution are used at levels known to those skilled in the art in order to improve the wearability of lenses and when used directly in the eye, to provide 5 increased resistance to infection. Inositol and other simple saccharides used in ophthalmic solutions increases preservative efficacy in certain formulations, provides increased resistance to infection in corneal tissue, in certain formulations, and improves the quality of tears in certain formulations.

The formulations may also include buffers such as phosphates, 10 bicarbonate, citrate, borate, ACES, BES, BICINE, BIS-Tris Propane, HEPES, HEPPS, imidazole, MES, MOPS, PIPES, TAPS, TES, and Tricine.

Surfactants that might be employed include polysorbate surfactants, polyoxyethylene surfactants, phosphonates, saponins and polyethoxylated castor oils, but preferably the polyethoxylated castor oils. These surfactants are commercially 15 available. The polyethoxylated castor oils are sold by BASF under the trademark Cremaphor.

The solutions of the present invention may contain other additives including but not limited to buffers, tonicity agents, demulcents, wetting agents, preservatives, sequestering agents (chelating agents), surface active agents, and 20 enzymes.

Other aspect include adding to the solution from 0.001 to 1 weight percent chelating agent (preferably disodium EDTA) and/or additional microbicide, (preferably 0.00001 to 0.1 or 0.00001 to 0.01) weight percent polyhexamethylene biquanide (PHMB), N-alkyl-2-pyrrolidone, chlorhexidine, polyquaternium-1, 25 hexetidine, bronopol, alexidine, low concentrations of hydrogen peroxide, and ophthalmologically acceptable salts thereof.

Ophthalmologically acceptable chelating agents useful in the present invention include amino carboxylic acid compounds or water-soluble salts thereof, including ethylenediaminetetraacetic acid, nitrilotriacetic acid, diethylenetriamine 30 pentaacetic acid, hydroxyethylethylenediaminetriacetic acid, 1,2-diaminocyclohexanetetraacetic acid, ethylene glycol bis (beta-aminoethyl ether) in N,

N, N', N' tetraacetic acid (EGTA), aminodiacetic acid and hydroxyethylamino diacetic acid. These acids can be used in the form of their water soluble salts, particularly their alkali metal salts. Especially preferred chelating agents are the di-, tri- and tetra-sodium salts of ethylenediaminetetraacetic acid (EDTA), most preferably 5 disodium EDTA (Disodium Edetate).

Other chelating agents such as citrates and polyphosphates can also be used in the present invention. The citrates which can be used in the present invention include citric acid and its mono-, di- and tri-alkaline metal salts. The polyphosphates which can be used include pyrophosphates, triphosphates, tetraphosphates, 10 trimetaphosphates, tetrametaphosphates, as well as more highly condensed phosphates in the form of the neutral or acidic alkali metal salts such as the sodium and potassium salts as well as the ammonium salt.

The pH of the solutions should be adjusted to be compatible with the eye and the contact lens, such as between 6.0 to 8.0, preferably between 6.8 to 7.8 or 15 between 7.0 to 7.6. Significant deviations from neutral (pH 7.3) will cause changes in the physical parameters (i.e., diameter) in some contact lenses. Low pH (pH less than 5.5) can cause burning and stinging of the eyes, while very low or very high pH (less than 3.0 or greater than 10) can cause ocular damage.

The additional preservatives employed in the present invention are known, 20 such as polyhexamethylene biguanide, N-alkyl-2-pyrrolidone, chlorhexidine, polyhexamethylene biguanide, alexidine, polyquaternium-1, hexetidine, bronopol and a very low concentration of hydrogen peroxide, e.g., 30 to 200 ppm.

The solutions of the invention are compatible with both rigid gas 25 permeable and hydrophilic contact lenses during storage, cleaning, wetting, soaking, rinsing and disinfection.

A typical aqueous solution of the present invention may contain additional ingredients which would not affect the basic and novel characteristics of the active ingredients described earlier, such as tonicity agents, surfactants and viscosity inducing agents, which may aid in either the lens cleaning or in providing lubrication 30 to the eye. Suitable tonicity agents include sodium chloride, potassium chloride, glycerol or mixtures thereof. The tonicity of the solution is typically adjusted to

approximately 240-310 milliosmoles per kilogram solution (mOsm/kg) to render the solution compatible with ocular tissue and with hydrophilic contact lenses. In one embodiment, the solution contains 0.01 to 0.2 weight percent sodium chloride. The important factor is to keep the concentrations of such additives to a degree no greater than that which would supply a chloride concentration of no greater than about 0.2 mole percent.

Suitable viscosity inducing agents can include lecithin or the cellulose derivatives such as hydroxymethylcellulose, hydroxypropylcellulose and methylcellulose in amounts similar to those for surfactants, above.

10 The contact lens solution as described herein may further comprise between 0.01% and 5.0% of glycerine and/or between 0.01% and 2.0% of decanedioic acid.

### **EXAMPLE 1 Pyridoxine**

15 Formulations containing pyridoxine HCl (Spectrum) and Thiamine HCl (Fisher) were prepared in a 0.2% phosphate buffer. The solutions were made isotonic with sodium chloride and preserved with polyhexamethylene biquanide at 0.0001%. The pH was adjusted to 7.2 with either 1 N sodium hydroxide or 1 N hydrochloric acid. The *in vitro* microbicidal activity of the solutions was determined by exposing *C. albicans* to 10 ml of each solution at room temperature for 4 hours. Subsequently, 20 an aliquot of each solution was serially diluted onto agar plates and incubated for 48 hours at elevated temperatures. At the conclusion of the incubation period the plates are examined for the development of colonies. The log reduction was determined based on a comparison to the inoculum control. The following table provides the results of the *in vitro* studies.

Additive	4 Hour Log Reduction
Pyridoxine HCl (0.5%)	2.0
Buffer Control	0.8

The solution containing pyridoxine HCl and thiamine HCl showed an improvement in the activity against *C. albicans* as compared to the buffer control.

2. **Patent: Expanded Thiamine and Pyridoxine (B Vitamins and  
5 B Vitamin Precursors)**

Example 2 Formulations containing dexpanthenol

Formulations containing dexpanthenol were prepared in a 0.2% phosphate buffer. The solutions were made isotonic with sodium chloride and preserved with polyhexamethylene biquanide at 0.0001%. The pH was adjusted to 7.2 with either 10 1 N sodium hydroxide or 1 N hydrochloric acid. The *in vitro* microbicidal activity of the solutions was determined by exposing *C. albicans* to 10 ml of each solution at room temperature for 4 hours. Subsequently, an aliquot of each solution was serially diluted onto agar plates and incubated for 48 hours at elevated temperatures. At the conclusion of the incubation period the plates were examined for the development of 15 colonies. The log reduction was determined based on a comparison to the inoculum control. The following table provides the results of the *in vitro* studies.

**Log**

<b>Reduction</b>	<b>Buffer</b>	<b>Preservative</b>	<b>Electrolyte</b>	<b>Additive</b>
2.16	None	PHMB 0.0001%	None	None
3.41	Bis-Tris Propane 0.2%	PHMB 0.0001%	None	Dexpanthenol

This data shows that the dexpanthenol has improved preservative efficacy over a solution with a preservative alone.

What is claimed is:

1. A contact lens solution comprising:

0.001 to 10 weight percent of a preservative enhancer chosen from the group consisting of thiamine (B1), riboflavin (B2), niacin (B3), dexpantenol, 5 panthenol, pantothenic acid (B5), pyridoxine (B6), and cobalamin (B12);

a cationic preservative;

a chloride concentration of no greater than about 0.2 mole percent; and

a suitable carrier.

2. The contact lens solution of claim 1, wherein said cationic preservative is

10 0.0001 to 0.01 weight percent of polyhexamethylene biguanide.

3. The contact lens solution of claim 1, further comprising a physiologically compatible buffer.

4. The contact lens solution of claim 3, wherein the physiological buffer is chosen from the group consisting of phosphate, bicarbonate, citrate, borate, ACES, 15 BES, BICINE, BIS-Tris Propane, HEPES, HEPPS, imidazole, MES, MOPS, PIPES, TAPS, TES, and Tricine.

5. The contact lens solution of claim 1, further comprising between 0.01% and 5.0% of glycerine.

6. The contact lens solution of claim 1, further comprising between 0.01% 20 and 2.0% of decanedioic acid.

7. The contact lens solution of claim 1, further comprising a wetting agent selected from the group consisting of polysorbate surfactants, polyoxyethylene surfactants, phosphonates, saponins, and polyethoxylated castor oils.

8. The contact lens solution of claim 1, further comprising a sequestering 25 agent selected from the group consisting as ethylenediaminetetraacetic acid, phosphonates, citrate, gluconate and tartarate.

9. An ophthalmic solution comprising:

0.0001 to about 1 weight percent of a preservative enhancer chosen from the group consisting of thiamine (B1), riboflavin (B2), niacin (B3), dexpanthenol, panthenol, pantothenic acid (B5), pyridoxine (B6), and cobalamin (B12);

5 a cationic preservative;

a chloride concentration of no greater than about 0.02 mole percent; and

a carrier.

10. Use of the contact lens solution of any one of claims 1 to 8 for treating a contact lens.